Printer Friendly

CANGENE RECEIVES UNITED STATES PATENT FOR NEW DRUG-PRODUCTION TECHNOLOGY

 TORONTO, April 7 /PRNewswire/ --Cangene Corporation today announced the issuance of U.S. Patent Number 5,200,568 covering the company's proprietary production system for making a wide range of recombinant proteins. The patent includes both method and product claims. One of the protein products specifically identified in the patent is LEUCOTROPIN(TM), Cangene's brand of granulocyte-macrophage colony- stimulating factor (GM-CSF). A member of a family of colony-stimulating factors, or CSF'S, GM-CSF stimulates the production of certain white blood cells in the body, helping to alleviate the serious side effects of some medical treatments, particularly cancer chemotherapy. Industry sources estimate that U.S. sales of colony-stimulating factors will reach $1.7 billion by the year 2000.
 ``The CSF market is both lucrative and competitive, and this patent issuance is commercially significant'', explained Dr. Eric James, chairman and CEO of Cangene. ``Several companies are involved in protracted interference proceedings which deal with GM-CSF related claims before the U.S. Patent and Trademark Office'', James said, ``and we are gratified to be able to remain above that fray and concentrate on moving our LEUCOTROPIN(TM) drug through the regulatory pathway as quickly as possible.'' Cangene's Phase I/II clinical trial of LEUCOTROPIN(TM) in Canadian cancer patients is virtually complete and the Phase II/III trials will follow when approved.
 The protein manufacturing system, known as CANGENUS(TM), utilizes STREPTOMYCES as host cells, in effect turning these organisms into miniature factories. Unlike other gene expression technologies which require numerous steps in order to achieve both purity and biological activity, CANGENUS(TM) is especially efficient in producing clean human proteins in biologically active form, thus greatly simplifying their production.
 The above patent also encompasses other proteins made using the CANGENUS(TM) technology, several of which follow LEUCOTROPIN(TM) in Cangene's developmental pathway. ``Therapeutic proteins for use as drugs are of the most value and are our primary interest,'' said Dr. Robert T. Garvin, co-founder and vice president of research. Cangene's second drug produced in CANGENUS(TM), an Interleukin-3 drug called ALLEVORIN(TM), has just finished preclinical trials.
 Cangene is a biotechnology company primarily focused on the commercial development of biopharmaceuticals. Concentrating mainly on blood cell growth factors, the company uses its patented manufacturing technology to produce high quality drugs for use in the treatment of cancer and AIDS. Cangene has also invented a diagnostic technology called NASBA(TM) which enables detection of disease and microbial contamination at the molecular level. Royalties from NASBA(TM) products are expected before the end of the company's July 31 fiscal year pursuant to its licensing agreement with Akzo Pharma International bv, Cangene's Dutch partner in the commercialization of NASBA(TM).
 -0- 4/7/93
 /CONTACT: Jean Compton, manager of investor relations of Cangene Corporation, 416-673-0200, or fax, 416-673-5123/


CO: Cangene Corporation ST: Ontario IN: MTC SU:

TM -- NY082 -- 3977 04/07/93 18:47 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 7, 1993
Words:478
Previous Article:BALTIMORE CO. (MD.) GO BONDS RATED 'AAA' BY FITCH -- FITCH FINANCIAL WIRE --
Next Article:OREGON $16.6 MILLION GENERAL OBLIGATION BONDS RATED 'AA' BY FITCH -- FITCH FINANCIAL WIRE --
Topics:


Related Articles
Neotherapeutics receives patent for bifunctional molecule technology platform.
NeoTherapeutics receives patent allowance for nerve regeneration.
La Jolla Pharmaceutical receives patent on stroke treatment.
Neotherapeutics receives patent for activating neurotrophic factors.
Aastrom receives patent covering integrated system for producing human cells.
Introgen's anti-cancer therapy in combination with established cancer treatments awarded patent.
NeoTherapeutics receives patent for purine-based technology.
Metabasis Therapeutics patents technology for teating liver disease.
Cortex Pharma receives notice of allowance of European patent.
Epicyte announces broad patent covering production of antibodies in plants.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters